APC与P53突变协同作用在晚期结直肠癌中创造NOTUM抑制的治疗易感性
该研究利用携带不同驱动突变组合的小鼠和人类结肠类器官,进行Notum功能获得与缺失研究,发现NOTUM在APC缺失腺瘤中保持抑癌活性,但在P53缺失进展为腺癌后成为必需癌基因,且药理学抑制NOTUM在临床前小鼠模型和人类类器官中有效抑制原发腺癌生长和远端器官转移定植。
要点
- NOTUM在APC缺失腺瘤中保持抑癌活性,尽管存在组成性β-catenin活性。
- 进展为P53缺失的腺癌后,NOTUM成为必需癌基因,且该表型不依赖Wnt。
- 药理学抑制NOTUM在临床前模型和人类类器官中有效抑制原发腺癌生长和转移定植。
核心结论
- 靶向细胞外酶NOTUM的单药在临床前小鼠模型和人类类器官中可有效治疗侵袭性转移性腺癌,使NOTUM及其glypican靶点成为晚期结直肠癌的治疗易感性。
研究设计与样本
- 使用工程化携带结直肠癌驱动突变组合的小鼠和人类结肠类器官进行Notum功能获得与缺失研究。
- 采用体外实验、体内内镜引导的原位类器官植入实验和转录组分析表征Notum活性效应。
- 使用Notum活性小分子抑制剂进行靶向致癌Notum活性的临床前治疗概念验证研究。
主要发现
- NOTUM在APC缺失腺瘤中保持抑癌活性,尽管存在组成性β-catenin活性。
- 进展为P53缺失的腺癌后,NOTUM成为必需癌基因。
- 这些表型不依赖Wnt,分别由NOTUM在早期与晚期疾病中对glypican 1和4的差异活性导致。
- 临床前小鼠模型和人类类器官培养显示,药理学抑制NOTUM在阻止原发腺癌生长和抑制远端器官转移定植方面高度有效。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with the majority of cases initiated by inactivation of the APC tumour suppressor. This results in the constitutive activation of canonical WNT pathway transcriptional effector ß-catenin, along with induction of WNT feedback inhibitors, including the extracellular palmitoleoyl-protein carboxylesterase NOTUM which antagonises WNT-FZD receptor-ligand interactions. Here, we sought to evaluate the effects of NOTUM activity on CRC as a function of driver mutation landscape. DESIGN: Mouse and human colon organoids engineered with combinations of CRC driver mutations were used for Notum genetic gain-of-function and loss-of-function studies. In vitro assays, in vivo endoscope-guided orthotopic organoid implantation assays and transcriptomic profiling were employed to characterise the effects of Notum activity. Small molecule inhibitors of Notum activity were used in preclinical therapeutic proof-of-principle studies targeting oncogenic Notum activity. RESULTS: NOTUM retains tumour suppressive activity in APC-null adenomas despite constitutive ß-catenin activity. Strikingly, on progression to adenocarcinoma with P53 loss, NOTUM becomes an obligate oncogene. These phenotypes are Wnt-independent, resulting from differential activity of NOTUM on glypican 1 and 4 in early-stage versus late-stage disease, respectively. Ultimately, preclinical mouse models and human organoid cultures demonstrate that pharmacological inhibition of NOTUM is highly effective in arresting primary adenocarcinoma growth and inhibiting metastatic colonisation of distal organs. CONCLUSIONS: Our findings that a single agent targeting the extracellular enzyme NOTUM is effective in treating highly aggressive, metastatic adenocarcinomas in preclinical mouse models and human organoids make NOTUM and its glypican targets therapeutic vulnerabilities in advanced CRC.
引用
- Tian Y, Wang X, Cramer Z, et al. APC and P53 mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer. Gut. 2023. PMID: 37591698. doi:10.1136/gutjnl-2022-329140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。